Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): ...

    2026-02-09

    DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Precision Chloride Channel Blocker for Translational Research

    Executive Summary: DIDS, supplied by APExBIO (SKU B7675), is a well-characterized anion transport inhibitor with high specificity for chloride channels such as ClC-Ka (IC50 = 100 μM) and ClC-ec1 (IC50 ≈ 300 μM) [product]. It reduces spontaneous transient inward currents (STICs) in muscle cells in a concentration-dependent manner and causes vasodilation in pressure-constricted cerebral arteries at an IC50 of 69 ± 14 μM. DIDS modulates TRPV1 channel function, enhancing agonist-induced currents in DRG neurons. In vivo, DIDS enhances hyperthermia-induced tumor growth suppression, particularly when combined with amiloride, and mitigates ischemia-hypoxia-induced white matter damage by inhibiting ClC-2 and reducing ROS, iNOS, TNF-α, and caspase-3 positive cells (Conod et al., 2022). The compound is insoluble in water, ethanol, and DMSO but can be dissolved at concentrations >10 mM in DMSO with warming or sonication. Stock solutions should be stored below –20°C and avoided for long-term solution storage.

    Biological Rationale

    Anion transport and chloride channel regulation are fundamental to cell volume control, membrane potential maintenance, and signaling in excitable and non-excitable cells. Dysregulation of chloride channel activity is implicated in diverse pathologies, including cancer metastasis, ischemia-induced neuronal injury, and vascular dysfunction (Conod et al., 2022). DIDS provides researchers with a tool for dissecting these ion-dependent processes by enabling selective, dose-dependent inhibition of key chloride channels. Its application in cellular and in vivo models clarifies the contributions of chloride flux to apoptosis, tumor microenvironment modulation, and neuroprotection.

    Mechanism of Action of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid)

    DIDS acts as a covalent, irreversible inhibitor of several chloride channels and anion exchangers. It binds to amino groups within the channel structure, blocking the transmembrane movement of Cl- ions. The most thoroughly characterized targets are the ClC-Ka chloride channel (IC50 = 100 μM) and the bacterial ClC-ec1 Cl-/H+ exchanger (IC50 ≈ 300 μM) (APExBIO Product Page). DIDS also inhibits voltage-gated chloride channel ClC-2, reducing downstream oxidative and inflammatory markers. In sensory neurons, DIDS enhances TRPV1 currents induced by capsaicin or low pH, suggesting functional modulation rather than simple blockade in some contexts. These multifaceted mechanisms underpin DIDS's utility in modeling chloride-dependent biological processes.

    Evidence & Benchmarks

    • DIDS inhibits ClC-Ka chloride channels with an IC50 of 100 μM in patch-clamp assays (https://www.apexbt.com/dids.html).
    • It reduces spontaneous transient inward currents (STICs) in muscle cells in a concentration-dependent manner (https://doi.org/10.1016/j.celrep.2022.110490; see methods).
    • Vasodilatory effects are observed in pressure-constricted cerebral artery smooth muscle cells, with an IC50 of 69 ± 14 μM (https://www.apexbt.com/dids.html).
    • DIDS enhances hyperthermia-induced tumor growth suppression in vivo, especially in combination with amiloride, extending tumor growth delay (https://doi.org/10.1016/j.celrep.2022.110490; results, tumor study).
    • It reduces ischemia-hypoxia-induced white matter damage in neonatal rat models via inhibition of ClC-2 and downregulation of ROS, iNOS, TNF-α, and caspase-3 (https://doi.org/10.1016/j.celrep.2022.110490; supplementary data).
    • DIDS modulates TRPV1 channel function in an agonist-dependent manner, enhancing currents induced by capsaicin or low pH in dorsal root ganglion neurons (https://www.apexbt.com/dids.html).

    For further protocol comparisons and troubleshooting, see the contrast in this workflow-focused guide, which emphasizes experimental design strategies, whereas this article details mechanistic specificity and evidence benchmarks.

    To review advanced troubleshooting and expert workflow optimizations, consult this applied workflows piece; the present article extends those insights with quantitative evidence and current best practices.

    For a mechanistic deep-dive into DIDS's role in metastatic cancer and neuroprotection models, this article provides a focused analysis, while the current dossier contextualizes the compound within broader translational research applications.

    Applications, Limits & Misconceptions

    DIDS is used widely in basic and translational research:

    • Cancer Research: Models tumor apoptosis, metastatic state acquisition, and microenvironment modulation via chloride channel inhibition.
    • Neuroprotection: Reduces ischemia-hypoxia-induced white matter loss, ROS, and apoptosis in neonatal and adult brain models.
    • Vascular Physiology: Investigates vasodilatory mechanisms and smooth muscle excitability in cerebral and peripheral vessels.
    • Channel Physiology: Dissects TRPV1 and ClC family channel function in excitable tissues.

    For purchase or further study, see DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) B7675 from APExBIO.

    Common Pitfalls or Misconceptions

    • DIDS is not a universal Cl- channel blocker: Its selectivity profile limits efficacy to certain ClC isoforms (e.g., ClC-Ka, ClC-2) and does not guarantee broad inhibition across all anion transporters.
    • Solubility issues: DIDS is insoluble in water, ethanol, and DMSO at low concentrations. Use >10 mM DMSO with warming or ultrasonication for preparation; avoid long-term solution storage.
    • Off-target effects possible at high concentrations: Very high doses may affect other proteins with nucleophilic amino groups.
    • Not suitable for chronic in vivo dosing: Due to irreversible binding and slow clearance, chronic studies may confound acute effects and toxicity.
    • No effect on channels lacking accessible amino nucleophiles: DIDS requires reactive amino acid residues for covalent modification.

    Workflow Integration & Parameters

    To maximize experimental reproducibility with DIDS (B7675):

    • Solubilization: Dissolve in DMSO at concentrations >10 mM; heat to 37°C or use ultrasonic bath for optimal dissolution.
    • Storage: Stock solutions should be stored at –20°C or below. Avoid repeated freeze-thaw cycles and prolonged solution storage.
    • Dosing: Use established IC50 values (e.g., 100 μM for ClC-Ka, 69 ± 14 μM for vascular models) as starting points; titrate as required by cell type and endpoint.
    • Controls: Always include vehicle and, where possible, non-covalent anion transport inhibitors for comparison.
    • Compatibility: Verify channel isoform expression and ensure no interfering compounds (e.g., reducing agents) are present in buffer.

    For protocol troubleshooting and comparative benchmarks, see this evidence-focused summary; this article provides updated IC50 values and recent in vivo data.

    Conclusion & Outlook

    DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a rigorously characterized anion transport inhibitor essential for dissecting chloride channel function in cancer, neuroprotection, and vascular physiology. Its defined selectivity, robust evidence base, and clear workflow parameters make it a benchmark tool for translational research. Ongoing studies continue to expand its applications, particularly in combination therapies and advanced disease models. For best practices and purchasing, refer to APExBIO’s B7675 product page. Researchers are encouraged to consider recent mechanistic insights and practical boundaries to ensure reproducible and interpretable results.